Multimodal hippocampal and amygdala subfield volumetry in polygenic risk for Alzheimer's disease

Amy N Murray1, Hannah L Chandler1, Thomas M Lancaster2

  • 1Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, United Kingdom.

Neurobiology of Aging
|November 23, 2020
PubMed

Insights

Alzheimer's disease polygenic risk scores are linked to reduced medial temporal lobe volumes, including specific hippocampal subfields, years before clinical symptoms appear. This finding may refine early Alzheimer's risk prediction and intervention strategies.

Area of Science:

  • Neuroimaging
  • Genetics
  • Alzheimer's Disease Research

Background:

  • Preclinical Alzheimer's disease (AD) models indicate medial temporal lobe (MTL) volume reduction precedes clinical onset.
  • Alzheimer's disease polygenic risk scores (PRS) correlate with reduced hippocampus/amygdala volumes, but subregion specificity is unclear.

Purpose of the Study:

  • To investigate the relationship between AD polygenic risk scores (PRS) and specific MTL subregions in young adults.
  • To identify novel associations between AD-PRS and hippocampal subfields predictive of future AD risk.

Main Methods:

  • Utilized a multimodal (T1w/T2w) neuroimaging approach in a large sample (N=730) of young participants (aged 22-35 years).
  • Analyzed the predictive power of AD-PRS for MTL volumes and specific hippocampal subregions using statistical modeling.

Main Results:

  • AD-PRS significantly predicted hippocampus/amygdala volumes and specific hippocampal subregions (pFDR < 0.05).
  • Observed negative associations between AD-PRS and overall hippocampal/amygdala volumes.
  • Identified novel links between AD-PRS and specific hippocampal subfields, including CA1 and the fissure (pFDR = 0.045 and 0.041, respectively).

Conclusions:

  • AD-PRS is associated with structural differences in specific MTL subfields decades before clinical AD onset.
  • These findings enhance understanding of early AD risk mechanisms and may inform targeted preclinical interventions.
  • Provides greater specificity for identifying individuals at high risk for Alzheimer's disease based on genetic and neuroimaging markers.